Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ice-CAP: Ipatasertib + Atezolizumab in Solid Tumors
NCT03673787Phase 2Active, not recruiting
- Sponsor
- The Institute of Cancer Research
- Start
- Aug 2018
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ipatasertib in solid tumor, glioblastoma (GBM), metastatic castration-resistant prostate cancer (mCRPC), melanoma, gynecologic cancer, sponsored by The Institute of Cancer Research. Started Aug 2018; status: active, not recruiting.
02
Drugs
ipatasertib
03
Conditions
solid tumorglioblastoma (GBM)metastatic castration-resistant prostate cancer (mCRPC)melanomagynecologic cancer
Beyond the preview
Go deeper on NCT03673787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03673787.